Same-day confirmation of infection and antimicrobial susceptibility profiling using flow cytometry.


Journal

EBioMedicine
ISSN: 2352-3964
Titre abrégé: EBioMedicine
Pays: Netherlands
ID NLM: 101647039

Informations de publication

Date de publication:
Aug 2022
Historique:
received: 20 02 2022
revised: 21 05 2022
accepted: 21 06 2022
pubmed: 22 7 2022
medline: 17 8 2022
entrez: 21 7 2022
Statut: ppublish

Résumé

The annual mortality burden of antimicrobial resistant infections exceeds 1.27 million/year. With serious infections, every hour without effective antimicrobial therapy results in a 6.7% increased risk of death. New technology that delivers actionable pathology results in clinically-relevant timeframes is an urgent priority. We present the development and validation of an acoustic-enhanced flow cytometric (AFC) workflow that provides same-day confirmation of infection and antimicrobial susceptibility, using peritoneal dialysis (PD)-associated peritonitis as a demonstrative example. In this cohort study, we analysed peritoneal dialysis effluent specimens using AFC to confirm the presence of infection and antimicrobial susceptibility of identified organisms. The primary outcome was the performance of the assay compared to conventional microbiology performed by the clinical laboratory. A secondary outcome was time to result. AFC confirmed infection from primary specimens (n=116), with a sensitivity of 86% and specificity of 94% in ≤ one hour from arrival, including confirmation of infecting organisms in culture-negative cases. Combined with flow-cytometry-assisted antimicrobial susceptibility testing (FAST), we demonstrate same-day antimicrobial susceptibility profiles with an accuracy equivalent to conventional laboratory-based tests. Application of AFC based assays to confirm infection and predict antimicrobial susceptibility can deliver actionable results with a performance that meets or exceeds currently utilised microbiological tests in clinically meaningful timeframes, as demonstrated for PD peritonitis. This technology shows potential for broad applicability to other time-critical serious infections. Government of Western Australia (Department of Health), Government of Australia (National Health and Medical Research Council) and the Forrest Research Foundation.

Sections du résumé

BACKGROUND BACKGROUND
The annual mortality burden of antimicrobial resistant infections exceeds 1.27 million/year. With serious infections, every hour without effective antimicrobial therapy results in a 6.7% increased risk of death. New technology that delivers actionable pathology results in clinically-relevant timeframes is an urgent priority. We present the development and validation of an acoustic-enhanced flow cytometric (AFC) workflow that provides same-day confirmation of infection and antimicrobial susceptibility, using peritoneal dialysis (PD)-associated peritonitis as a demonstrative example.
METHODS METHODS
In this cohort study, we analysed peritoneal dialysis effluent specimens using AFC to confirm the presence of infection and antimicrobial susceptibility of identified organisms. The primary outcome was the performance of the assay compared to conventional microbiology performed by the clinical laboratory. A secondary outcome was time to result.
FINDINGS RESULTS
AFC confirmed infection from primary specimens (n=116), with a sensitivity of 86% and specificity of 94% in ≤ one hour from arrival, including confirmation of infecting organisms in culture-negative cases. Combined with flow-cytometry-assisted antimicrobial susceptibility testing (FAST), we demonstrate same-day antimicrobial susceptibility profiles with an accuracy equivalent to conventional laboratory-based tests.
INTERPRETATION CONCLUSIONS
Application of AFC based assays to confirm infection and predict antimicrobial susceptibility can deliver actionable results with a performance that meets or exceeds currently utilised microbiological tests in clinically meaningful timeframes, as demonstrated for PD peritonitis. This technology shows potential for broad applicability to other time-critical serious infections.
FUNDING BACKGROUND
Government of Western Australia (Department of Health), Government of Australia (National Health and Medical Research Council) and the Forrest Research Foundation.

Identifiants

pubmed: 35864063
pii: S2352-3964(22)00326-7
doi: 10.1016/j.ebiom.2022.104145
pmc: PMC9386725
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Anti-Infective Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104145

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests Kieran Mulroney (KM), Christine Carson (CC), Teagan Paton (TP), and Timothy Inglis (TI) declare financial interest arising from agreements pertaining to a provisional patent covering part of the work presented in this study. KM, CC, and TI declare loan of flow cytometry equipment and donation of reagents from ThermoFisher Scientific that partially supported the work presented in this study.

Références

BMC Microbiol. 2015 Feb 18;15:36
pubmed: 25881030
Nat Rev Nephrol. 2017 Feb;13(2):90-103
pubmed: 28029154
Curr Protoc Cytom. 2018 Apr;84(1):e36
pubmed: 30040220
Kidney Int Rep. 2016 Jun 11;1(2):65-72
pubmed: 29142915
Lancet. 2022 Feb 12;399(10325):629-655
pubmed: 35065702
Adv Exp Med Biol. 2019;1165:3-15
pubmed: 31399958
Am J Kidney Dis. 2010 Apr;55(4):690-7
pubmed: 20110144
Microbiology (Reading). 2010 Nov;156(Pt 11):3216-3223
pubmed: 20705661
Nephrol Dial Transplant. 2013 Aug;28(8):2139-45
pubmed: 23743015
Int J Nephrol Renovasc Dis. 2018 Jun 11;11:173-186
pubmed: 29928142
J Med Microbiol. 2020 May;69(5):657-669
pubmed: 31665100
J Appl Microbiol. 2020 Oct;129(4):806-822
pubmed: 32418295
Rev Argent Microbiol. 2008 Jan-Mar;40(1):17-23
pubmed: 18669048
Am J Kidney Dis. 2012 Jul;60(1):102-11
pubmed: 22417786
Indian J Nephrol. 2013 Jan;23(1):12-7
pubmed: 23580799
Nat Rev Microbiol. 2019 Jan;17(1):51-62
pubmed: 30333569
Perit Dial Int. 2015 Dec;35(7):722-8
pubmed: 26152579
Sci Rep. 2017 May 15;7(1):1903
pubmed: 28507322
Diagnostics (Basel). 2019 May 03;9(2):
pubmed: 31058811
Cochrane Database Syst Rev. 2021 May 4;5:CD013235
pubmed: 34097767
BMC Biol. 2014 Nov 12;12:87
pubmed: 25387460
Kidney Int. 2020 Jun;97(6):1253-1259
pubmed: 32359809

Auteurs

Kieran Mulroney (K)

Harry Perkins Institute of Medical Research, 6 Verdun Street, Nedlands, WA 6009, Australia; School of Medicine, University of Western Australia, 35 Stirling Highway, Crawley, WA 6009, Australia.

Margaret Kopczyk (M)

Harry Perkins Institute of Medical Research, 6 Verdun Street, Nedlands, WA 6009, Australia.

Christine Carson (C)

School of Biomedical Science, University of Western Australia, 35 Stirling Highway, Crawley, WA 6009, Australia; PathWest Laboratory Medicine WA, PP Block, QEII Medical Centre, Hospital Avenue, Nedlands, WA 6009, Australia.

Teagan Paton (T)

Harry Perkins Institute of Medical Research, 6 Verdun Street, Nedlands, WA 6009, Australia; PathWest Laboratory Medicine WA, PP Block, QEII Medical Centre, Hospital Avenue, Nedlands, WA 6009, Australia.

Timothy Inglis (T)

School of Medicine, University of Western Australia, 35 Stirling Highway, Crawley, WA 6009, Australia; School of Biomedical Science, University of Western Australia, 35 Stirling Highway, Crawley, WA 6009, Australia; PathWest Laboratory Medicine WA, PP Block, QEII Medical Centre, Hospital Avenue, Nedlands, WA 6009, Australia.

Aron Chakera (A)

Harry Perkins Institute of Medical Research, 6 Verdun Street, Nedlands, WA 6009, Australia; School of Medicine, University of Western Australia, 35 Stirling Highway, Crawley, WA 6009, Australia; Department of Renal Medicine, Sir Charles Gairdner Hospital, QEII Medical Centre, Hospital Avenue, Nedlands, WA 6009, Australia. Electronic address: aron.chakera@uwa.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH